<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02909751</url>
  </required_header>
  <id_info>
    <org_study_id>NeoToc</org_study_id>
    <nct_id>NCT02909751</nct_id>
  </id_info>
  <brief_title>Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer</brief_title>
  <acronym>NeoToc</acronym>
  <official_title>Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vejle Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vejle Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether tocotrienol can improve the effect and
      reduce the side effects of standard chemotherapy before operation for breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 14, 2016</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Actual">January 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological complete response</measure>
    <time_frame>26 weeks from date of inclusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of changes in NK-cells with pathological complete response</measure>
    <time_frame>26 weeks from date of inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of changes in ctDNA with pathological complete response</measure>
    <time_frame>26 weeks from date of inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with grade 3-4 side effects</measure>
    <time_frame>29 weeks from date of inclusion</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HER2 negative:
Four cycles of 3-weekly epirubicin 90 mg/m2 iv and cyclophosphamid 600 mg/m2 iv followed by Four cycles of taxane, i.e. 3-weekly docetaxel 100 mg/m2 iv or weekly paclitaxel 80 mg/m2 iv
HER2 positive:
Four cycles of taxane, i.e. 3-weekly docetaxel 100 mg/m2 iv or weekly paclitaxel 80 mg/m2 iv + 3-weekly trastuzumab (8 mg/kg iv saturation, then 6 mg/kg iv) and possibly pertuzumab (840 mg saturation, then 420 mg iv) followed by Four cycles of 3-weekly epirubicin 90 mg/m2 iv and cyclophosphamid 600 mg/m2 iv</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neoadjuvant chemotherapy + tocotrienol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HER2 negative:
Four cycles of 3-weekly epirubicin 90 mg/m2 iv and cyclophosphamid 600 mg/m2 iv followed by Four cycles of taxane, i.e. 3-weekly docetaxel 100 mg/m2 iv or weekly paclitaxel 80 mg/m2 iv.
Daily: Tocotrienol 300 mg x 3
HER2 positive:
Four cycles of taxane, i.e. 3-weekly docetaxel 100 mg/m2 iv or weekly paclitaxel 80 mg/m2 iv + 3-weekly trastuzumab (8 mg/kg iv saturation, then 6 mg/kg iv) and possibly pertuzumab (840 mg saturation, then 420 mg iv) followed by Four cycles of 3-weekly epirubicin 90 mg/m2 iv and cyclophosphamid 600 mg/m2 iv.
Daily: Tocotrienol 300 mg x 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin 90 mg/m2 iv</intervention_name>
    <description>Max. 3 months</description>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
    <arm_group_label>Neoadjuvant chemotherapy + tocotrienol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide 600 mg/m2 iv</intervention_name>
    <description>Max. 3 months</description>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
    <arm_group_label>Neoadjuvant chemotherapy + tocotrienol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel 100 mg/m2 iv OR paclitaxel 80 mg/m2 iv</intervention_name>
    <description>Max. 3 months</description>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
    <arm_group_label>Neoadjuvant chemotherapy + tocotrienol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab 8 mg/kg iv saturation, then 6 mg/kg iv (HER2 positive patients only)</intervention_name>
    <description>Max. 3 months.</description>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
    <arm_group_label>Neoadjuvant chemotherapy + tocotrienol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pertuzumab 840 mg iv saturation, then 420 mg iv (selected HER2 positive patients only)</intervention_name>
    <description>Max. 3 months</description>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
    <arm_group_label>Neoadjuvant chemotherapy + tocotrienol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Tocotrienol 300 mg x 3 daily</intervention_name>
    <description>Max. 6 months</description>
    <arm_group_label>Neoadjuvant chemotherapy + tocotrienol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with histologically verified breast cancer (adenocarcinoma)

          -  Age ≥ 18 years.

          -  Neoadjuvant treatment indicated according to departmental guidelines

          -  PS 0-2 and suited for surgery.

          -  Normal heart function, LVEF ≥ 50% by MUGA/ECHO in patients receiving neoadjuvant
             trastuzumab

          -  Normal bone marrow function: Hemoglobin ≥ 6 mmol/l; ANC ≥ 1.5x10^9/l; Thrombocytes ≥
             100x10^9/l.

          -  Normal liver function: Bilirubin ≤ 1.5 x upper level of normal, ALAT ≤ 2.5 x upper
             level of normal, BASP ≤ 2.5 x upper level of normal.

          -  Normal kidney function: Creatinine ≤ upper level of normal. In case of increased
             creatinine, measured/calculated GFR must be ≥ 50 ml/min.

          -  Fertile women must present a negative pregnancy test and use a safe contraceptive
             during and 3 months after the treatment. Intrauterine device without hormone is
             considered safe.

          -  Written and orally informed consent

        Exclusion Criteria:

          -  Bilateral breast cancer or suspected dissemination. Verified by bilateral mammography,
             bone scintigraphy, chest and abdomen CT, and PET-CT.

          -  Pregnant and breastfeeding women

          -  Mental or social conditions that will prevent treatment or follow-up

          -  Other simultaneous experimental treatment

          -  Immunosuppressive treatment (other than prednisolone during neoadjuvant chemotherapy)

          -  Vitamin or nutritional supplements (other than multivitamin tablet and calcium tablet
             with vitamin D)

          -  Active or latent viral/bacterial infection

          -  Rheumatoid arthritis or other autoimmune disease

          -  Other malignant disease within the past 5 years excl. non-melanoma cancer of the skin
             and carcinoma in situ cervicis uteri.

          -  Previous treatment with docetaxel, paclitaxel, epirubicin, cyclophosphamide,
             trastuzumab, pertuzumab or tocotrienol

          -  Hypersensitivity to any of the active or auxiliary substances
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erik H Jakobsen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Vejle Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vejle hospital, Department of Oncology</name>
      <address>
        <city>Vejle</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 16, 2016</study_first_submitted>
  <study_first_submitted_qc>September 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2016</study_first_posted>
  <last_update_submitted>May 13, 2020</last_update_submitted>
  <last_update_submitted_qc>May 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

